Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of the Early Introduction of Everolimus (Certican) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Next Previous
Trial Profile

Safety and Efficacy of the Early Introduction of Everolimus (Certican) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use

Most Recent Events

  • 18 Nov 2015 New trial record
  • 30 Jun 2014 Primary endpoint of a composite variable of the incidence of efficacy failure including biopsy-proven acute rejection, graft loss, death, or loss to follow-up until 12 months after transplantation has not been met, according to results published in the Transplantation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top